Predict your next investment

Endo International company logo
Corporation
HEALTHCARE | Pharmaceuticals / Drugs
endo.com

See what CB Insights has to offer

Portfolio Exits

5

Partners & Customers

10

Service Providers

1

About Endo International

Endo International is a global specialty healthcare company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic and device products through its operating companies. Endo has global headquarters in Dublin, Ireland, and US headquarters in Malvern, PA.

Endo International Headquarter Location

Simmonscourt Road

Dublin,

Ireland

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Endo International Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Endo International Rank

Latest Endo International News

Endo International (ENDP) Stock Moves -0.9%: What You Should Know

Jan 21, 2022

Endo International (ENDP) closed at $3.32 in the latest trading session, marking a -0.9% move from the prior day. This story originally appeared on Zacks Endo International (ENDP) closed the most recent trading day at $3.32, moving -0.9% from the previous trading session. This move was narrower than the S&P 500's daily loss of 1.1%. Elsewhere, the Dow lost 0.89%, while the tech-heavy Nasdaq added 0.03%. - Zacks Heading into today, shares of the health care company had lost 18.89% over the past month, lagging the Medical sector's loss of 7.84% and the S&P 500's loss of 1.81% in that time. Endo International will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of $0.67, down 10.67% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $734.44 million, down 3.39% from the year-ago period. Investors should also note any recent changes to analyst estimates for Endo International. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 7.31% lower. Endo International is currently a Zacks Rank #3 (Hold). Looking at its valuation, Endo International is holding a Forward P/E ratio of 1.46. This represents a discount compared to its industry's average Forward P/E of 15.81. The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 37% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. As one investor put it, “curing and preventing hundreds of diseases…what should that market be worth?” This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.

Endo International Portfolio Exits

5 Portfolio Exits

Endo International has 5 portfolio exits. Their latest portfolio exit was Endo International - ANDAs on August 06, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/6/2021

Divestiture

1

7/5/2017

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

6/3/2014

Divestiture

Subscribe to see more

Subscribe to see more

10

1/10/2014

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

8/12/2013

Divestiture

Subscribe to see more

Subscribe to see more

10

Date

8/6/2021

7/5/2017

6/3/2014

1/10/2014

8/12/2013

Exit

Divestiture

Acq - Fin

Divestiture

Acq - Fin

Divestiture

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Endo International Acquisitions

13 Acquisitions

Endo International acquired 13 companies. Their latest acquisition was BioSpecifics Technologies on December 02, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/2/2020

$99M

Merger

4

4/26/2018

$99M

Acquired

1

5/18/2015

$99M

Acquired

1

10/9/2014

Series D

Subscribe to see more

$99M

$99M

Subscribe to see more

10

8/7/2014

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/2/2020

4/26/2018

5/18/2015

10/9/2014

8/7/2014

Investment Stage

Series D

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$99M

Note

Merger

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

4

1

1

10

10

Endo International Partners & Customers

10 Partners and customers

Endo International has 10 strategic partners and customers. Endo International recently partnered with Isofol on November 11, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

11/5/2020

Licensor

Isofol

Sweden

Isofol Medical AB’s License Agreement With Endo Ventures Limited

Isofol Medical AB entered into a definitive license agreement with Endo Ventures Limited , a subsidiary of Endo International plc , for the registration and commercialization of Isofol Medical AB 's proprietary drug candidate arfolitixorin on an exclusive basis in Canada .

1

9/25/2020

Client

Novavax

United States

Endo International to help Novavax bring COVID-19 vaccine to the public

Endo International subsidiary , Par Sterile Products enters into a non-exclusive agreement with Novavax to provide fill-finish manufacturing services at its plant in Rochester , Michigan for NVX-CoV2373 , Novavax ' COVID-19 vaccine candidate .

2

9/8/2020

Licensor

BioSpecifics Technologies

United States

BioSpecifics Technologies : to Present at the H.C. Wainwright Virtual Healthcare Conference

The Company discovered and developed a proprietary form of injectable collagenase , which is currently marketed by the Company 's partner , Endo International plc , as XIAFLEX ® in North America for the treatment of Dupuytren 's contracture and Peyronie 's disease .

2

8/27/2018

Partner

BioDelivery Sciences International

United States

Subscribe to see more

Subscribe to see more

10

6/5/2017

Licensor

Veloxis Pharmaceuticals

Denmark

Subscribe to see more

Subscribe to see more

10

Date

11/5/2020

9/25/2020

9/8/2020

8/27/2018

6/5/2017

Type

Licensor

Client

Licensor

Partner

Licensor

Business Partner

Isofol

Novavax

BioSpecifics Technologies

BioDelivery Sciences International

Veloxis Pharmaceuticals

Country

Sweden

United States

United States

United States

Denmark

News Snippet

Isofol Medical AB’s License Agreement With Endo Ventures Limited

Isofol Medical AB entered into a definitive license agreement with Endo Ventures Limited , a subsidiary of Endo International plc , for the registration and commercialization of Isofol Medical AB 's proprietary drug candidate arfolitixorin on an exclusive basis in Canada .

Endo International to help Novavax bring COVID-19 vaccine to the public

Endo International subsidiary , Par Sterile Products enters into a non-exclusive agreement with Novavax to provide fill-finish manufacturing services at its plant in Rochester , Michigan for NVX-CoV2373 , Novavax ' COVID-19 vaccine candidate .

BioSpecifics Technologies : to Present at the H.C. Wainwright Virtual Healthcare Conference

The Company discovered and developed a proprietary form of injectable collagenase , which is currently marketed by the Company 's partner , Endo International plc , as XIAFLEX ® in North America for the treatment of Dupuytren 's contracture and Peyronie 's disease .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

2

10

10

Endo International Service Providers

1 Service Provider

Endo International has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P, and Acquired

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P, and Acquired

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Endo International Team

36 Team Members

Endo International has 36 team members, including current Chief Executive Officer, President, Blaise Coleman.

Name

Work History

Title

Status

Blaise Coleman

Chief Executive Officer, President

Current

Mark Bradley

Chief Financial Officer

Current

Terry Coughlin

Chief Operating Officer, Executive Vice President

Current

Susan Williamson

Chief Compliance Officer, Senior Vice President

Current

Ravi Tayi MD MPH

Chief Medical Officer

Current

Name

Blaise Coleman

Mark Bradley

Terry Coughlin

Susan Williamson

Ravi Tayi MD MPH

Work History

Title

Chief Executive Officer, President

Chief Financial Officer

Chief Operating Officer, Executive Vice President

Chief Compliance Officer, Senior Vice President

Chief Medical Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.